UBS Group
IBIO icon

UBS Group’s iBio IBIO Stock Holding History

UBS Group’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.13K Sell
2,173
-124,383
-98% -$289K ﹤0.01% 8983
2025
Q4 		$244K Buy
126,556
+126,555
+12,655,500% +$173K ﹤0.01% 6473
2025
Q3 		$1 Sell
1
-28,602
-100% -$22K ﹤0.01% 10268
2025
Q2 		$21.8K Buy
28,603
+2,713
+10% +$2.94K ﹤0.01% 8373
2025
Q1 		$104K Buy
25,890
+24,991
+2,780% +$97.1K ﹤0.01% 7023
2024
Q4 		$2.2K Buy
899
+898
+89,800% +$2.31K ﹤0.01% 9093
2024
Q3 		$2 Sell
1
-40,668
-100% -$80.3K ﹤0.01% 9415
2024
Q2 		$85.8K Buy
40,669
+38,792
+2,067% +$83.4K ﹤0.01% 6297
2024
Q1 		$7.62K Sell
1,877
-16,123
-90% -$20.3K ﹤0.01% 7373
2023
Q4 		$24.7K Buy
18,000
+16,965
+1,639% +$74.1K ﹤0.01% 6977
2023
Q3 		$6.27K Buy
1,035
+1,030
+20,600% +$8.9K ﹤0.01% 7311
2023
Q2 		$60 Sell
5
-267
-98% -$5.04K ﹤0.01% 8580
2023
Q1 		$11.3K Sell
272
-197
-42% -$5.07K ﹤0.01% 7513
2022
Q4 		$4.13K Buy
469
+359
+326% +$12.1K ﹤0.01% 9381
2022
Q3 		$9K Buy
110
+105
+2,100% +$14.5K ﹤0.01% 8577
2022
Q2 		$1K Sell
5
-73
-94% -$11K ﹤0.01% 9881
2022
Q1 		$17K Sell
78
-156
-67% -$32.6K ﹤0.01% 7651
2021
Q4 		$65K Buy
+234
New +$89.2K ﹤0.01% 6684
2021
Q3 		– Sell
-47
Closed -$35K – 9775
2021
Q2 		$35K Sell
47
-53
-53% -$38.7K ﹤0.01% 6769
2021
Q1 		$77K Buy
100
+34
+52% +$29.6K ﹤0.01% 6162
2020
Q4 		$35K Buy
66
+61
+1,220% +$49.7K ﹤0.01% 6502
2020
Q3 		$5K Sell
5
-26
-84% -$37.7K ﹤0.01% 7304
2020
Q2 		$35K Buy
31
+30
+3,000% +$19.6K ﹤0.01% 6162
2020
Q1 		$0 Sell
1
-196
-99% -$75.4K ﹤0.01% 8150
2019
Q4 		$25K Buy
197
+180
+1,059% +$24.4K ﹤0.01% 6748
2019
Q3 		$5K Hold
17
– – ﹤0.01% 7470
2019
Q2 		$6K Hold
17
– – ﹤0.01% 7311
2019
Q1 		$8K Sell
17
-10
-37% -$4.34K ﹤0.01% 6939
2018
Q4 		$10K Buy
27
+10
+59% +$3.87K ﹤0.01% 7232
2018
Q3 		$7K Sell
17
-1
-6% -$405 ﹤0.01% 7328
2018
Q2 		$8K Sell
18
-17
-49% -$12.9K ﹤0.01% 7256
2018
Q1 		$38K Buy
35
+17
+94% +$17.8K ﹤0.01% 5918
2017
Q4 		$16K Sell
18
-4
-18% -$5.13K ﹤0.01% 6725
2017
Q3 		$35K Buy
22
+1
+5% +$1.61K ﹤0.01% 6050
2017
Q2 		$41K Buy
21
+15
+250% +$29.4K ﹤0.01% 5796
2017
Q1 		$13K Buy
6
+4
+200% +$8.32K ﹤0.01% 6451
2016
Q4 		$5K Buy
+2
New +$4.65K ﹤0.01% 7239
2016
Q3 		– Sell
-7
Closed -$22K – 7517
2016
Q2 		$25K Buy
7
+6
+600% +$19.6K ﹤0.01% 6110
2016
Q1 		$2K Sell
1
-3
-75% -$8.6K ﹤0.01% 7310
2015
Q4 		$10K Buy
4
+2
+100% +$6.38K ﹤0.01% 7278
2015
Q3 		$7K Buy
2
+1
+100% +$3.71K ﹤0.01% 7501
2015
Q2 		$6K Sell
1
-2
-67% -$9.3K ﹤0.01% 7786
2015
Q1 		$12K Sell
3
-1
-25% -$3.39K ﹤0.01% 7488
2014
Q4 		$12K Buy
+4
New +$21.4K ﹤0.01% 8223

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

UBS Group's IBIO Position: Q1 2026 in Review

UBS Group reduced its iBio (IBIO) stake by 98% in Q1 2026, selling an estimated $289K and leaving 2,173 shares worth $4.13K. The position accounts for ﹤0.01% of the portfolio, ranked #8983.

UBS Group first reported a position in IBIO in Q4 2014 and has held it in 44 quarters since. The position peaked at $244K in Q4 2025. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

  • UBS Group held 2,173 shares of iBio worth $4.13K as of Q1 2026.
  • UBS Group sold 124,383 iBio shares in Q1 2026, an estimated $289K.
  • iBio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8983 holding.
  • UBS Group first reported a position in iBio in Q4 2014 and has held it in 44 quarters since.
  • UBS Group's iBio position peaked at $244K in Q4 2025.
  • 52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.